NASDAQ:BIOR

Biora Therapeutics (BIOR) Stock Forecast, Price & News

$4.49

+0.07 (+1.58%)

(As of 06/2/2023 ET)

Compare

Today's Range: $4.41
▼
$4.78
50-Day Range: $2.31
▼
$4.85
52-Week Range: $1.95
▼
$28.75

Volume: 124,135 shs
Average Volume: 1.46 million shs
Market Capitalization: $53.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3,750.00

Biora Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 83,418.9% Upside
$3,750.00 Price Target
Short Interest: Healthy
3.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.69) to ($4.77) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

610th out of 983 stocks

Pharmaceutical Preparations Industry

302nd out of 486 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $3,750.00, Biora Therapeutics has a forecasted upside of 83,418.9% from its current price of $4.49.
Amount of Analyst Coverage
Biora Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.45% of the float of Biora Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Biora Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biora Therapeutics has recently decreased by 7.66%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Biora Therapeutics does not currently pay a dividend.
Dividend Growth
Biora Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BIOR.

0.6

News and Social Media Coverage

Search Interest
18 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biora Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.24% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.13% of the stock of Biora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biora Therapeutics are expected to grow in the coming year, from ($6.69) to ($4.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biora Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biora Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Biora Therapeutics (NASDAQ:BIOR) Stock

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BIOR Stock News Headlines

May 20, 2023 | americanbankingnews.com

HC Wainwright Brokers Boost Earnings Estimates for Biora Therapeutics, Inc. (NASDAQ:BIOR)

May 17, 2023 | finance.yahoo.com

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2023 Earnings Call Transcript

June 2, 2023 | Behind the Markets (Ad)

⚡ 2,467% Return on Israeli Laser Company?

This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.

May 17, 2023 | americanbankingnews.com

Biora Therapeutics, Inc. Forecasted to Post Q2 2023 Earnings of ($1.60) Per Share (NASDAQ:BIOR)

May 16, 2023 | finance.yahoo.com

Q1 2023 Biora Therapeutics Inc Earnings Call

May 16, 2023 | finanznachrichten.de

Biora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 15, 2023 | benzinga.com

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 15, 2023 | msn.com

Recap: Biora Therapeutics Q1 Earnings

June 2, 2023 | Behind the Markets (Ad)

⚡ 2,467% Return on Israeli Laser Company?

May 15, 2023 | finance.yahoo.com

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 14, 2023 | americanbankingnews.com

Biora Therapeutics (BIOR) Scheduled to Post Quarterly Earnings on Monday

May 12, 2023 | msn.com

Earnings Preview: Biora Therapeutics

May 8, 2023 | finance.yahoo.com

Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update

May 1, 2023 | finance.yahoo.com

Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer

April 26, 2023 | forbes.com

A Recession Looks More Likely, And Google And Tesla CEO’s Both Praise And Raise Concerns About AI - Forbes AI Newsletter April 22nd

April 22, 2023 | americanbankingnews.com

Horizon Therapeutics Public (NASDAQ:HZNP) & Biora Therapeutics (NASDAQ:BIOR) Head-To-Head Survey

April 20, 2023 | finance.yahoo.com

Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference

April 5, 2023 | finance.yahoo.com

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2022 Earnings Call Transcript

April 1, 2023 | benzinga.com

Biora Therapeutics Stock (NASDAQ:BIOR), Dividends

March 31, 2023 | finanznachrichten.de

Biora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

March 31, 2023 | msn.com

Biora Therapeutics Earnings Perspective: Return On Invested Capital

March 30, 2023 | finance.yahoo.com

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

March 29, 2023 | benzinga.com

Earnings Preview For Biora Therapeutics

March 29, 2023 | americanbankingnews.com

Biora Therapeutics (BIOR) to Release Quarterly Earnings on Thursday

March 23, 2023 | finance.yahoo.com

Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

March 1, 2023 | msn.com

What Does Biora Therapeutics' Debt Look Like?

February 23, 2023 | finance.yahoo.com

Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist

See More Headlines

BIOR Price History

30 days | 90 days | 365 days | Advanced Chart

BIOR Company Calendar

Today: 6/02/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BIOR
CUSIP: N/A
CIK: 1580063
Web: www.bioratherapeutics.com
Phone: 833-727-2841
Fax: N/A
Employees: 642
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3,750.00
High Stock Price Forecast: $3,750.00
Low Stock Price Forecast: $3,750.00
Forecasted Upside/Downside: +82,317.6%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,160,000.00
Net Margins: -20,895.00%
Pretax Margin: -26,100.50%
Return on Equity: N/A
Return on Assets: -84.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.48
Quick Ratio: 1.48

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 174.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($8.85) per share
Price / Book: -0.51

Miscellaneous

Outstanding Shares: 11,860,000
Free Float: 8,154,000
Market Cap: $53.96 million
Optionable: Optionable
Beta: 1.16

Key Executives

Mr. Aditya P. Mohanty M.B.A. (Age 56)
CEO & Director
Comp: $383.76k

Mr. Eric d'Esparbes (Age 55)
Chief Financial Officer
Comp: $619.3k

Mr. Clarke Neumann J.D. (Age 59)
Gen. Counsel & Sec.
Comp: $712.02k

Eric Fox
VP of Fin. & Accounting & Treasurer

Mr. Troy Seelye (Age 59)
Chief Information Officer

Mr. George Gianakopoulos (Age 62)
Sr. VP of Sales

Ms. Robyn Hatton
Head of HR

Mr. Kevin Howe Ph.D.
Sr. VP of Strategic Operations

Dr. Sharat Singh Ph.D. (Age 64)
Head of Research

Dr. Paul Shabram M.B.A.
Head of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIOR Stock - Frequently Asked Questions

What is Biora Therapeutics' stock price forecast for 2023?: 0 equities research analysts have issued 1 year target prices for Biora Therapeutics' shares. Their BIOR share price forecasts range from $3,750.00 to $3,750.00. On average, they expect the company's share price to reach $3,750.00 in the next twelve months. This suggests a possible upside of 82,317.6% from the stock's current price.
View analysts price targets for BIOR or view top-rated stocks among Wall Street analysts.
How have BIOR shares performed in 2023?: Biora Therapeutics' stock was trading at $82.3125 at the start of the year. Since then, BIOR stock has decreased by 94.5% and is now trading at $4.55.
View the best growth stocks for 2023 here.
Are investors shorting Biora Therapeutics?: Biora Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 390,700 shares, a drop of 7.7% from the April 30th total of 423,100 shares. Based on an average daily trading volume, of 142,000 shares, the days-to-cover ratio is currently 2.8 days. Currently, 3.5% of the shares of the company are sold short.
View Biora Therapeutics' Short Interest.
When is Biora Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our BIOR earnings forecast.
When did Biora Therapeutics' stock split?: Biora Therapeutics shares reverse split on Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What is Biora Therapeutics' stock symbol?: Biora Therapeutics trades on the NASDAQ under the ticker symbol "BIOR."

Who are Biora Therapeutics' major shareholders?: Biora Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.55%), Simplex Trading LLC (0.00%), Geode Capital Management LLC (0.37%), Schonfeld Strategic Advisors LLC (0.36%), Susquehanna International Group LLP (0.00%) and Group One Trading L.P. (0.00%).
View institutional ownership trends.
How do I buy shares of Biora Therapeutics?: Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biora Therapeutics' stock price today?: One share of BIOR stock can currently be purchased for approximately $4.55.
How much money does Biora Therapeutics make?: Biora Therapeutics (NASDAQ:BIOR) has a market capitalization of $53.96 million and generates $310,000.00 in revenue each year. The company earns $-38,160,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis.
How many employees does Biora Therapeutics have?: The company employs 642 workers across the globe.
How can I contact Biora Therapeutics?: Biora Therapeutics' mailing address is 4330 La Jolla Village Dr Ste 200, San Diego, California 92122. The official website for the company is www.bioratherapeutics.com. The company can be reached via phone at 833-727-2841 or via email at ir@progenity.com.

This page (NASDAQ:BIOR) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial